Using Whole Genome Sequencing (WGS) of 3256 Patients with Hematologic Malignancies to Determine Genome Instability

Conclusions:High TMB is rare in hematological neoplasms, and our data across all entities suggest that the acquisition of mutations over age should be a major contributing factor.While TP53 and a few other factors are well studied, using genome-wide datasets in the near future will allow to deeply understand the broad patterns or signatures of genome stability (incl. copy number or structural variants) and their prognostic or predictive value.DisclosuresBaer: MLL Munich Leukemia Laboratory: Employment. Hutter: MLL Munich Leukemia Laboratory: Employment. Höllein: MLL Munich Leukemia Laboratory: Employment. Walter: MLL Munich Leukemia Laboratory: Employment. Meggendorfer: MLL Munich Leukemia Laboratory: Employment. Kern: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach: MLL Munich Leukemia Laboratory: Employment, Equity Ownership.

Source: Blood - November 21, 2018 Category: Hematology Authors: Baer, C., Hutter, S., Hollein, A., Walter, W., Meggendorfer, M., Kern, W., Haferlach, C., Haferlach, T. Tags: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III Source Type: research